Suzuki Keisuke, Okuma Yasuyuki, Hattori Nobutaka, Kamei Satoshi, Yoshii Fumihito, Utsumi Hiroya, Iwasaki Yasuo, Iijima Mutsumi, Miyamoto Tomoyuki, Miyamoto Masayuki, Hirata Koichi
Department of Neurology, Dokkyo Medical University, Tochigi, Japan.
Mov Disord. 2007 Jul 15;22(9):1245-51. doi: 10.1002/mds.21257.
The present multicenter cross-sectional study was performed using semistructured questionnaires to determine the contributing factors of sleep disturbances in Japanese patients with Parkinson's disease (PD). We used the Parkinson's disease sleep scale (PDSS, Japanese version). All data were obtained by means of interviewed questionnaire and physical examination by neurologists. The study was carried out between April 2005 and December 2005 at eight university hospitals and affiliated facilities in the Kanto area of Japan. A total of 188 (85 men and 103 women) PD patients and 144 controls (64 men and 80 women) were included. Stepwise regression analysis identified complications of treatment, depression, age, and disease duration as significant risk factors of sleep disturbances in PD. Significant differences in total PDSS score were observed between Hoehn & Yahr (H&Y) Stages 1 and 4, between H&Y Stages 2 and 4, and between H&Y stages 3 and 4 (Bonferroni test). The results of this survey suggested that complications due to treatment (dyskinesia, wearing off, on-off), depressive state, and disease stage are significant determinants of sleep disorders in Japanese patients with PD. We speculate that the reduction of neurotransmitters involved in the sleep-wakefulness mechanism and degeneration of neurons progress together in parallel with deterioration of motor function.
本多中心横断面研究采用半结构化问卷来确定日本帕金森病(PD)患者睡眠障碍的影响因素。我们使用了帕金森病睡眠量表(PDSS,日文版)。所有数据均通过访谈问卷和神经科医生的体格检查获得。该研究于2005年4月至2005年12月在日本关东地区的八所大学医院及附属机构进行。共纳入了188例(85名男性和103名女性)PD患者和144名对照者(64名男性和80名女性)。逐步回归分析确定治疗并发症、抑郁、年龄和病程是PD患者睡眠障碍的显著危险因素。在Hoehn & Yahr(H&Y)1期和4期之间、2期和4期之间以及3期和4期之间观察到PDSS总分存在显著差异(Bonferroni检验)。本次调查结果表明,治疗并发症(异动症、剂末现象、开关现象)、抑郁状态和疾病分期是日本PD患者睡眠障碍的重要决定因素。我们推测,参与睡眠 - 觉醒机制的神经递质减少和神经元变性与运动功能恶化同时并行进展。